Disease burden and patient characteristics associated with systemic therapy utilization among adults with atopic dermatitis: data from CorEvitas Atopic Dermatitis Registry
Background The decision to initiate advanced systemics in patients with atopic dermatitis (AD) is complex.Objectives To explore disease burden and clinical characteristics of patients with moderate-to-severe AD and identify characteristics associated with initiating new systemics.Methods Data from p...
Saved in:
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2024-12-01
|
| Series: | Journal of Dermatological Treatment |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/09546634.2024.2396382 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1846119599765979136 |
|---|---|
| author | Jonathan I. Silverberg Linda Stein Gold Seemal Desai Alexandra Golant Douglas DiRuggiero D. Christian Fenske Alvin Li Zach Dawson Yolanda Muñoz Maldonado Kaylee Ho Kayla Callahan Eric L. Simpson |
| author_facet | Jonathan I. Silverberg Linda Stein Gold Seemal Desai Alexandra Golant Douglas DiRuggiero D. Christian Fenske Alvin Li Zach Dawson Yolanda Muñoz Maldonado Kaylee Ho Kayla Callahan Eric L. Simpson |
| author_sort | Jonathan I. Silverberg |
| collection | DOAJ |
| description | Background The decision to initiate advanced systemics in patients with atopic dermatitis (AD) is complex.Objectives To explore disease burden and clinical characteristics of patients with moderate-to-severe AD and identify characteristics associated with initiating new systemics.Methods Data from prospective, longitudinal, non-interventional CorEvitas AD Registry were evaluated. Differences in demographic and clinical characteristics, comorbidities, disease severity (vIGA-AD™; body surface area (BSA); Eczema Area and Severity Index (EASI); SCORing AD [SCORAD]), and patient-reported outcomes (PROs) were assessed between systemic and non-systemic therapy groups.Results Of 883 patients, 673 were newly prescribed systemics and 210 were not. Non-systemic therapy group had higher than expected rates of severe disease at enrollment based on vIGA-AD = 4 (39%), mean BSA involvement (31%), and mean EASI (19). PROs for non-systemic therapy group indicated elevated burden from AD on quality of life and poor disease control. SCORAD, peak pruritus in the past 24 h, history of biologics, and facial pallor, were significantly associated with initiation of systemics at enrollment.Conclusion While disease burden likely influences the initiation of systemic therapy, many patients with significant burden are not treated with systemics for unclear reasons. Further research is needed to identify other factors, beyond disease severity, that influence this decision. |
| format | Article |
| id | doaj-art-1119ecf923d74df5a918939330f05f4f |
| institution | Kabale University |
| issn | 0954-6634 1471-1753 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Journal of Dermatological Treatment |
| spelling | doaj-art-1119ecf923d74df5a918939330f05f4f2024-12-16T22:53:48ZengTaylor & Francis GroupJournal of Dermatological Treatment0954-66341471-17532024-12-0135110.1080/09546634.2024.2396382Disease burden and patient characteristics associated with systemic therapy utilization among adults with atopic dermatitis: data from CorEvitas Atopic Dermatitis RegistryJonathan I. Silverberg0Linda Stein Gold1Seemal Desai2Alexandra Golant3Douglas DiRuggiero4D. Christian Fenske5Alvin Li6Zach Dawson7Yolanda Muñoz Maldonado8Kaylee Ho9Kayla Callahan10Eric L. Simpson11Division of Dermatology, The George Washington University School of Medicine & Health Sciences, Washington, District of Columbia, USADivision of Dermatology, Henry Ford Health System, Detroit, Michigan, USAInnovative Dermatology, Texas, Pennsylvania, USADepartment of Dermatology, Icahn School of Medicine at Mount Sinai, New York, New York, USASkin Cancer and Cosmetic Dermatology Center, Rome, Georgia, USAEli Lilly and Company, Indianapolis, Indiana, USACorEvitas LLC, Waltham, Massachusetts, USAEli Lilly and Company, Indianapolis, Indiana, USACorEvitas LLC, Waltham, Massachusetts, USACorEvitas LLC, Waltham, Massachusetts, USACorEvitas LLC, Waltham, Massachusetts, USADepartment of Dermatology, Oregon Health & Science University, Portland, Oregon, USABackground The decision to initiate advanced systemics in patients with atopic dermatitis (AD) is complex.Objectives To explore disease burden and clinical characteristics of patients with moderate-to-severe AD and identify characteristics associated with initiating new systemics.Methods Data from prospective, longitudinal, non-interventional CorEvitas AD Registry were evaluated. Differences in demographic and clinical characteristics, comorbidities, disease severity (vIGA-AD™; body surface area (BSA); Eczema Area and Severity Index (EASI); SCORing AD [SCORAD]), and patient-reported outcomes (PROs) were assessed between systemic and non-systemic therapy groups.Results Of 883 patients, 673 were newly prescribed systemics and 210 were not. Non-systemic therapy group had higher than expected rates of severe disease at enrollment based on vIGA-AD = 4 (39%), mean BSA involvement (31%), and mean EASI (19). PROs for non-systemic therapy group indicated elevated burden from AD on quality of life and poor disease control. SCORAD, peak pruritus in the past 24 h, history of biologics, and facial pallor, were significantly associated with initiation of systemics at enrollment.Conclusion While disease burden likely influences the initiation of systemic therapy, many patients with significant burden are not treated with systemics for unclear reasons. Further research is needed to identify other factors, beyond disease severity, that influence this decision.https://www.tandfonline.com/doi/10.1080/09546634.2024.2396382Atopic dermatitissystemic therapytopical therapydisease burden |
| spellingShingle | Jonathan I. Silverberg Linda Stein Gold Seemal Desai Alexandra Golant Douglas DiRuggiero D. Christian Fenske Alvin Li Zach Dawson Yolanda Muñoz Maldonado Kaylee Ho Kayla Callahan Eric L. Simpson Disease burden and patient characteristics associated with systemic therapy utilization among adults with atopic dermatitis: data from CorEvitas Atopic Dermatitis Registry Journal of Dermatological Treatment Atopic dermatitis systemic therapy topical therapy disease burden |
| title | Disease burden and patient characteristics associated with systemic therapy utilization among adults with atopic dermatitis: data from CorEvitas Atopic Dermatitis Registry |
| title_full | Disease burden and patient characteristics associated with systemic therapy utilization among adults with atopic dermatitis: data from CorEvitas Atopic Dermatitis Registry |
| title_fullStr | Disease burden and patient characteristics associated with systemic therapy utilization among adults with atopic dermatitis: data from CorEvitas Atopic Dermatitis Registry |
| title_full_unstemmed | Disease burden and patient characteristics associated with systemic therapy utilization among adults with atopic dermatitis: data from CorEvitas Atopic Dermatitis Registry |
| title_short | Disease burden and patient characteristics associated with systemic therapy utilization among adults with atopic dermatitis: data from CorEvitas Atopic Dermatitis Registry |
| title_sort | disease burden and patient characteristics associated with systemic therapy utilization among adults with atopic dermatitis data from corevitas atopic dermatitis registry |
| topic | Atopic dermatitis systemic therapy topical therapy disease burden |
| url | https://www.tandfonline.com/doi/10.1080/09546634.2024.2396382 |
| work_keys_str_mv | AT jonathanisilverberg diseaseburdenandpatientcharacteristicsassociatedwithsystemictherapyutilizationamongadultswithatopicdermatitisdatafromcorevitasatopicdermatitisregistry AT lindasteingold diseaseburdenandpatientcharacteristicsassociatedwithsystemictherapyutilizationamongadultswithatopicdermatitisdatafromcorevitasatopicdermatitisregistry AT seemaldesai diseaseburdenandpatientcharacteristicsassociatedwithsystemictherapyutilizationamongadultswithatopicdermatitisdatafromcorevitasatopicdermatitisregistry AT alexandragolant diseaseburdenandpatientcharacteristicsassociatedwithsystemictherapyutilizationamongadultswithatopicdermatitisdatafromcorevitasatopicdermatitisregistry AT douglasdiruggiero diseaseburdenandpatientcharacteristicsassociatedwithsystemictherapyutilizationamongadultswithatopicdermatitisdatafromcorevitasatopicdermatitisregistry AT dchristianfenske diseaseburdenandpatientcharacteristicsassociatedwithsystemictherapyutilizationamongadultswithatopicdermatitisdatafromcorevitasatopicdermatitisregistry AT alvinli diseaseburdenandpatientcharacteristicsassociatedwithsystemictherapyutilizationamongadultswithatopicdermatitisdatafromcorevitasatopicdermatitisregistry AT zachdawson diseaseburdenandpatientcharacteristicsassociatedwithsystemictherapyutilizationamongadultswithatopicdermatitisdatafromcorevitasatopicdermatitisregistry AT yolandamunozmaldonado diseaseburdenandpatientcharacteristicsassociatedwithsystemictherapyutilizationamongadultswithatopicdermatitisdatafromcorevitasatopicdermatitisregistry AT kayleeho diseaseburdenandpatientcharacteristicsassociatedwithsystemictherapyutilizationamongadultswithatopicdermatitisdatafromcorevitasatopicdermatitisregistry AT kaylacallahan diseaseburdenandpatientcharacteristicsassociatedwithsystemictherapyutilizationamongadultswithatopicdermatitisdatafromcorevitasatopicdermatitisregistry AT ericlsimpson diseaseburdenandpatientcharacteristicsassociatedwithsystemictherapyutilizationamongadultswithatopicdermatitisdatafromcorevitasatopicdermatitisregistry |